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The NO/cGMP signaling pathway plays an important role
in vasorelaxation and blood pressure regulation. The pre-
dominant effector of cGMP in vascular smooth muscle is
cGMP kinase I (cGK I). Established substrates of cGK I in
vascular smooth muscle are the large-conductance volt-
age- and Ca2+-activated (BK) potassium channel, the IP3-
receptor-associated cGMP kinase substrate (IRAG) and
the myosin phophatase 1 M. Previously, we identified the
cysteine-rich protein 2 (CRP2) in blood vessels as a new
substrate of cGK I which is specifically phosphorylated by
cGK I in vivo. However, the physiological role of CRP2 and
its involvement in regulation of vascular tone as an effec-
tor of cGMP/cGK I signaling was not known. To elucidate
the functional role of CRP2 in vascular smooth muscle,
we generated CRP2-deficient (CRP2-/-) mice. The myo-
genic tone of CRP2-/- tibial small arteries towards stepwise
pressure changes revealed no differences when compared
to wild type (wt). Unexpectedly, cGMP-mediated relaxa-
tion was enhanced in CRP2-/- tibial small arteries and A.
saphena. In contrast to cGMP, the cAMP-mediated relaxa-
tion was not affected in these vessels. Long-term radiotel-
emetric recordings revealed a significantly decreased
mean arterial pressure (MAP) and an enhanced NO/
cGMP signaling in CRP2-/- mice compared to wt. In-depth
analysis revealed increased protein levels of cGK I,
whereas the expression of cGK I targets such as BK channel
and IRAG was not altered in CRP2-/- vessels compared to
wt. Interactor screens with CRP2 as a bait revealed a spe-
cific interaction with a translation initiation factor. These
findings suggest that CRP2 is a specific effector of the vas-
cular NO/cGMP/cGK I signaling in vivo. CRP2 seems to be
involved in the regulation of the NO/cGMP/cGK I signal-
ing pathway by modulating cGK I expression. In addition,
the CRP2-/- mouse line may serve as an animal model for
hypotonia.
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